This week in Other Barks & Bites: the USPTO issues a final rule on trademark fee adjustments at the agency and also extends the public comment period for soliciting input on the agency’s exercise of discretion in institution trials at the PTAB; the UKIPO issues updates to post-Brexit rules narrowing acceptable Addresses for Service on agency filings; the Federal Circuit affirms a $90 million infringement verdict against GlaxoSmithKline’s sale of Ellipta inhalers, and rules that the Supreme Court’s decision in Thryv renders non-appealable the PTAB’s determination of a challenged patent’s eligibility for covered business method (CBM) review; GM announces a $7 billion increase to the company’s now-$27 billion plan to invest in electric vehicle and autonomous vehicle development; the ITC rescinds limited exclusion and cease and desist orders entered in a Section 337 proceeding brought by Rovi against Comcast; and the Second Circuit revives trademark infringement claims after finding bad faith in defendant’s employee emails regarding the development of a car air freshener designed to create consumer confusion.

Full Article Available Here